{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:32:43Z","timestamp":1787149963795,"version":"build-2736575974"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficiency and operational risks of preparing two forms of fluorouracil (solution and powder) for injection in the Pharmacy Intravenous Admixture Service (PIVAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted to assess a total of 100 preparation records of two forms (solution and powder; 50 records each) of fluorouracil at a tertiary hospital from May 2024 to December 2025. The configuration efficiency was assessed by the time spent and the number of configuration steps; the operational risks were evaluated by operational abnormalities and adverse events recorded in the PIVAS management system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The average preparation time for solution-form fluorouracil was significantly shorter than that of the powder-form counterpart [(673.58\u2009\u00b1\u2009279.74) seconds vs. (1049.34\u2009\u00b1\u2009540.48) seconds, P\u2009&lt;\u20090.05], with a reduction of over 42.86% in preparation steps (\u22644 steps vs.\u2009\u2265\u20097 steps). Two adverse events occurred with powder-form fluorouracil during the analysis period: one involved the formation of insoluble particles after drug reconstitution, and the other was due to operational error leading to liquid leakage. No adverse events were reported in relation to solution-form fluorouracil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In scenarios of limited resources or high workloads in the PIVAS, it is advisable to prioritize the use of solution-form fluorouracil under certain conditions to enhance efficiency and reduce operational risks. The findings may provide some clinical evidence for optimizing clinical dosage form and risk management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261476587","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:35:30Z","timestamp":1785944130000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preparation efficiency and operational risk of two dosage forms of fluorouracil in PIVAS workflow: A retrospective comparative study"],"prefix":"10.1177","author":[{"given":"Huo-Shu","family":"Chen","sequence":"first","affiliation":[{"name":"The Fifth Hospital of Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Su","sequence":"additional","affiliation":[{"name":"The Fifth Hospital of Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"The Fifth Hospital of Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Xu","sequence":"additional","affiliation":[{"name":"The Fifth Hospital of Xiamen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7430-6902","authenticated-orcid":false,"given":"Wen-Qiong","family":"He","sequence":"additional","affiliation":[{"name":"The Fifth Hospital of Xiamen"},{"name":"Pharmaceutical Affairs Comprehensive Management Professional Quality Control Center of Xiamen, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7029"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90532-z"},{"key":"e_1_3_3_4_2","unstructured":"Xuedong W Yueping W Juan G et al. ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Scientific reports 2017."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050653"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.97686"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28010306"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092175"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054288"},{"key":"e_1_3_3_10_2","first-page":"1","article-title":"Cisplatin, fluorouracil in bolus injection, and leucovorin in first-line therapy for advanced gastric cancer as an alternative to protocols with infusional fluorouracil","volume":"5","author":"Coelho RC","year":"2019","unstructured":"Coelho RC, Abreu PDP, Monteiro MR, et al. Cisplatin, fluorouracil in bolus injection, and leucovorin in first-line therapy for advanced gastric cancer as an alternative to protocols with infusional fluorouracil. J Glob Oncol 2019; 5: 1\u20138.","journal-title":"J Glob Oncol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2023.04.001"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231152618"},{"key":"e_1_3_3_13_2","first-page":"100487","article-title":"Research on PIVAS risk assessment and control strategy based on quality risk management (QRM)","volume":"15","author":"Qiu Q","year":"2024","unstructured":"Qiu Q, Zhu G, Peng G, et al. Research on PIVAS risk assessment and control strategy based on quality risk management (QRM). Explor Res Clin Soc Pharm 2024; 15: 100487. Published 2024 Aug 8.","journal-title":"Explor Res Clin Soc Pharm"},{"key":"e_1_3_3_14_2","article-title":"Intravenous compounding robots in pharmacy intravenous admixture services: a systematic review","volume":"102","author":"Yang C","year":"2023","unstructured":"Yang C, Ni X, Zhang L, et al. Intravenous compounding robots in pharmacy intravenous admixture services: a systematic review. Medicine (Baltimore) 2023; 102: e33476.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4769883"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015912"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000001047"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106590"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/anae.70122"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2008.029785"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2579882"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027676"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2196\/51921"},{"key":"e_1_3_3_24_2","first-page":"131","article-title":"Intravenous admixture preparation considerations, part 9-A: error prevention in intravenous admixture preparation","volume":"25","author":"Allen LV","year":"2021","unstructured":"Allen LVJr. Intravenous admixture preparation considerations, part 9-A: error prevention in intravenous admixture preparation. Int J Pharm Compd 2021; 25: 131\u2013139.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-021-01310-6"},{"key":"e_1_3_3_26_2","first-page":"364","article-title":"Filling the gaps on the institute for safe medication practices (ISMP) do not crush list for immediate-release products","volume":"25","author":"Uttaro E","year":"2021","unstructured":"Uttaro E, Zhao F, Schweighardt A. Filling the gaps on the institute for safe medication practices (ISMP) do not crush list for immediate-release products. Int J Pharm Compd 2021; 25: 364\u2013371.","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2004.011957"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261476587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261476587","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261476587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:10:15Z","timestamp":1787148615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261476587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":26,"alternative-id":["10.1177\/10781552261476587"],"URL":"https:\/\/doi.org\/10.1177\/10781552261476587","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"10781552261476587"}}